Publications by authors named "Steven Sambevski"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

254

Total Likes

0

Extended Reach

3,660

Social Features

4
E
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.
Dinesh Khanna, Toby M Maher, Elizabeth R Volkmann, Yannick Allanore, Vanessa Smith, Shervin Assassi, Michael Kreuter, Anna-Maria Hoffmann-Vold, Masataka Kuwana, Christian Stock

RMD Open· February 2023

Videos about Article: user

1 3 3

View All Article and Social Media Activity
O
Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies.
Elizabeth R Volkmann, Shervin Assassi, Christopher P Denton, Rozeta Simonovska, Steven Sambevski

J Rheumatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis.
Jeffrey A Sparks, Philippe Dieudé, Anna-Maria Hoffmann-Vold, Gerd R Burmester, Simon Lf Walsh, Steven Sambevski

BMC Rheumatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
Yannick Allanore, Dinesh Khanna, Vanessa Smith, Martin Aringer, Anna-Maria Hoffmann-Vold, Steven Sambevski

Rheumatology (Oxford)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
Elizabeth R Volkmann, Michael Kreuter, Anna M Hoffmann-Vold, Marlies Wijsenbeek, Vanessa Smith, Steven Sambevski

Rheumatology (Oxford)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Elisabetta Patorno, Ajinkya Pawar, Jessica M Franklin, Mehdi Najafzadeh, Anouk Déruaz-Luyet, Steven Sambevski

Circulation· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
David Fitchett, Silvio E Inzucchi, Christopher P Cannon, Darren K McGuire, Benjamin M Scirica, Steven Sambevski

Circulation· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis